A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.-论文-万方医学网

第一作者： Benjamin,Izar

第一单位： Beth Israel Deaconess Medical Center, Boston, Massachusetts.

作者： Benjamin,Izar ^[1] ; William,Sharfman ^[2] ; F Stephen,Hodi ^[3] ; Donald,Lawrence ^[4] ; Keith T,Flaherty ^[5] ; Ravi,Amaravadi ^[6] ; Kevin B,Kim ^[6] ; Igor,Puzanov ^[7] ; Jeffrey,Sosman ^[7] ; Reinhard,Dummer ^[8] ; Simone M,Goldinger ^[9] ; Lyhping,Lam ^[9] ; Shefali,Kakar ^[10] ; Zhongwen,Tang ^[10] ; Oliver,Krieter ^[11] ; David F,McDermott ^[12] ; Michael B,Atkins ^[12]

作者单位： Beth Israel Deaconess Medical Center, Boston, Massachusetts. ^[1] Center for Cancer Precision Medicine/Dana-Farber Cancer Institute and the Broad Institute, Boston, Massachusetts. ^[2] Broad Institute of MIT and Harvard, Cambridge, Massachusetts. ^[3] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. ^[4] Dana Farber Cancer Institute, Boston, Massachusetts. ^[5] Massachusetts General Hospital, Boston, Massachusetts. ^[6] Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania. ^[7] California Pacific Medical Center Research Institute, San Francisco, California. ^[8] Vanderbilt-Ingram Cancer Center, Vanderbilt, Tennessee. ^[9] University Hospital, Zurich, Switzerland. ^[10] Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts. ^[11] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. ^[12] Novartis Pharma AG, Basel, Switzerland. ^[13] Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia. ^[14]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);药物监测(Drug Monitoring);女(雌)性(Female);人类(Humans);咪唑类(Imidazoles);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);黑色素瘤(Melanoma);中年人(Middle Aged);分子靶向治疗(Molecular Targeted Therapy);突变(Mutation);肿瘤转移(Neoplasm Metastasis);肿瘤分期(Neoplasm Staging);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);吡啶类(Pyridines);治疗结果(Treatment Outcome)

DOI 10.1002/cam4.1140

PMID 28719152

发布时间 2021-01-09

检索历史清除

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Cancer medicine

相似文献

Cancer medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Cancer medicine

相似文献

Cancer medicine

相关期刊

检索历史清除